124 related articles for article (PubMed ID: 22301939)
1. Potential correlation between plasma total GIP levels and body mass index in Japanese patients with types 1 or 2 diabetes mellitus.
Kamoi K; Shinozaki Y; Furukawa K; Sasaki H
Endocr J; 2012; 59(4):353-63. PubMed ID: 22301939
[TBL] [Abstract][Full Text] [Related]
2. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
3. Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus.
Bonde L; Vilsbøll T; Nielsen T; Bagger JI; Svare JA; Holst JJ; Larsen S; Knop FK
Diabetes Obes Metab; 2013 Aug; 15(8):713-20. PubMed ID: 23406269
[TBL] [Abstract][Full Text] [Related]
4. Meal test for glucose-dependent insulinotropic peptide (GIP) in obese and type 2 diabetic patients.
Skrha J; Hilgertová J; Jarolímková M; Kunešová M; Hill M
Physiol Res; 2010; 59(5):749-755. PubMed ID: 20406045
[TBL] [Abstract][Full Text] [Related]
5. Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1.
Sonne DP; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
Eur J Endocrinol; 2014 Oct; 171(4):407-19. PubMed ID: 24986531
[TBL] [Abstract][Full Text] [Related]
6. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
[TBL] [Abstract][Full Text] [Related]
7. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
[TBL] [Abstract][Full Text] [Related]
8. Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion.
Mingrone G; Nolfe G; Gissey GC; Iaconelli A; Leccesi L; Guidone C; Nanni G; Holst JJ
Diabetologia; 2009 May; 52(5):873-81. PubMed ID: 19229515
[TBL] [Abstract][Full Text] [Related]
9. Impact of incretin on early-phase insulin secretion and glucose excursion.
Shen J; Chen Z; Chen C; Zhu X; Han Y
Endocrine; 2013 Oct; 44(2):403-10. PubMed ID: 23283820
[TBL] [Abstract][Full Text] [Related]
10. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.
Jones IR; Owens DR; Vora J; Luzio SD; Hayes TM
Diabetes Res Clin Pract; 1989 Nov; 7(4):263-9. PubMed ID: 2693029
[TBL] [Abstract][Full Text] [Related]
11. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Christensen MB; Calanna S; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2014 Mar; 99(3):E418-26. PubMed ID: 24423311
[TBL] [Abstract][Full Text] [Related]
12. Gastric inhibitory polypeptide in obesity and diabetes mellitus.
Service FJ; Rizza RA; Westland RE; Hall LD; Gerich JE; Go VL
J Clin Endocrinol Metab; 1984 Jun; 58(6):1133-40. PubMed ID: 6373812
[TBL] [Abstract][Full Text] [Related]
13. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial.
Heimbürger SMN; Hoe B; Nielsen CN; Bergmann NC; Hartmann B; Holst JJ; Vilsbøll T; Dejgaard TF; Christensen MB; Knop FK
Diabetologia; 2021 Nov; 64(11):2425-2431. PubMed ID: 34405256
[TBL] [Abstract][Full Text] [Related]
14. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
[TBL] [Abstract][Full Text] [Related]
15. Incretin secretion in obese Korean children and adolescents with newly diagnosed type 2 diabetes.
Park SH; Jung MH; Cho WK; Park MS; Suh BK
Clin Endocrinol (Oxf); 2016 Jan; 84(1):72-9. PubMed ID: 25903996
[TBL] [Abstract][Full Text] [Related]
16. Gastric inhibitory polypeptide responses and glucose turnover rates after natural meals in type II diabetic patients.
Osei K; Falko JM; O'Dorisio TM; Fields PG; Bossetti B
J Clin Endocrinol Metab; 1986 Feb; 62(2):325-30. PubMed ID: 3510224
[TBL] [Abstract][Full Text] [Related]
17. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
[TBL] [Abstract][Full Text] [Related]
18. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin.
Osonoi T; Saito M; Hariya N; Goto M; Mochizuki K
Peptides; 2016 Dec; 86():118-125. PubMed ID: 27780736
[TBL] [Abstract][Full Text] [Related]
19. Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes.
Wice BM; Reeds DN; Tran HD; Crimmins DL; Patterson BW; Dunai J; Wallendorf MJ; Ladenson JH; Villareal DT; Polonsky KS
Diabetes; 2012 Jul; 61(7):1793-800. PubMed ID: 22522617
[TBL] [Abstract][Full Text] [Related]
20. Decreased active GLP-1 response following large test meal in patients with type 1 diabetes using bolus insulin analogues.
Kamoi K; Shinozaki Y; Furukawa K; Sasaki H
Endocr J; 2011; 58(10):905-11. PubMed ID: 21878743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
